ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · Real-Time Price · USD

2.150

+0.070 (3.37%)

Nov 24, 2025, 4:00 PM EST - Market closed

ImmunityBio Employees

ImmunityBio had 680 employees as of December 31, 2024. The number of employees increased by 52 or 8.28% compared to the previous year.

Employees

680

Change (1Y)

52

Growth (1Y)

8.28%

Revenue / Employee

$121,404

Profits / Employee

-$512,671

Market Cap

2.12B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	680	52	8.28%
Dec 31, 2023	628	-97	-13.38%
Dec 31, 2022	725	138	23.51%
Dec 31, 2021	587	322	121.51%
Dec 31, 2019	265	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

IBRX News

5 days ago - ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech - Seeking Alpha
11 days ago - New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - Business Wire
20 days ago - Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 - Business Wire
4 weeks ago - Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks - Benzinga
7 weeks ago - ImmunityBio: A Small Bet Is Warranted - Seeking Alpha
2 months ago - ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking - Seeking Alpha
2 months ago - ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - Business Wire
3 months ago - Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Business Wire